Eighteen patients with uncomplicated degenerative joint disease requiring joint replacement (hip or knee) were given a single 2-g intravenous dose of aztreonam over a 5-min period preoperatively. The mean concentration in synovial fluid of 83.0 9.2 >g/ml averaged 0.99 times the concomitant levels in serum. The mean concentration in cancellous bone of 16.0 4.3 Lg/g averaged 0.20 times the concomitant levels in serum.
The increasing incidence of gram-negative bone and joint infections (14, 19) , particularly in patients with underlying diseases (13), combined with a higher incidence of poor therapeutic outcome in patients with such infections treated with available antimicrobial agents (10, 29) , has stimulated a search for improved therapeutic modalities. Aztreonam, a monobactam agent with excellent gram-negative antibacterial activity, is being evaluated as a treatment for gramnegative bacillary osteomyelitis and arthritis. This paper presents data from a clinical study designed to determine penetration of aztreonam into bone and synovial fluid.
Patients admitted to the orthopedic service of RushPresbyterian-St. Luke's Medical Center, Chicago, Ill., requiring elective hip or knee joint replacement were Serum was assayed by previously reported methods (20) . Standard preparations of bone and synovial fluid containing known amounts of aztreonam were prepared and assayed daily. Microbiological assay of bone was performed by a procedure similar to that used for prostate tissue in a previously reported study (17) , except that the samples were pulverized with a Spex freezer-mill prior to assay. The limit of detection of the assay was 0.1 ,ug/g of bone. The coefficient of variation and mean recovery from standards were 8.0 and 79.0%, respectively.
Bone samples were prepared for high-pressure liquid chromatography by a procedure identical to that used for the bioassay and then filtered (Millex; 0.45 pum [pore size]; Millipore Corp., Bedford, Mass.). They were then analyzed with a high-pressure liquid chromatography system consisting of an Altex model 11OA pump set for 2 ml/min, a 37-to 50-,um silica gel precolumn, a 30-to 38-,um C18 guard column, a Waters Associates, Inc., 10-,um ,Bondpak analytical column (150 by 3.9 mm), and a UV detector set for 290 nm. The mobile phase was 85 parts 5 mM tetrabutylammonium sulfate, adjusted to pH 2.85 with 1 M KH2PO4, and 15 parts acetonitrile. Samples were introduced via a 20-,u precision loop injector. The limit of detection was 1 ,ug/g, the coefficient of variation was 8.1%, and the mean recovery from standards was 87.0%.
The method used for microbiological assay of synovial fluid was identical to that previously reported for urine (20) , except that samples were diluted 1:20 in 0.1 M phosphate buffer (pH 6) prior to assay. The limit of detection was 0.4 ,g/ml. The coefficient of variation and mean recovery were 3.5 and 98%, respectively. The high-pressure liquid chromatographic assay of synovial fluid was done by a method identical to that previously reported for serum (20) . The limit of detection was 0.5 ,ug/ml. The coefficient of variation and recovery from standards were 8.5 and 98%, respectively.
Assays of hemoglobin in blood, bone, and synovial fluid and correction of aztreonam concentrations for blood contamination were performed by previously described methods (17) . Samples whose blood contents were 51% or more were excluded from analysis. No 83 ,ug/ml, and the average ratio of the concentration in synovial fluid to that in serum was 0.99. Although drug concentrations in synovial fluid were variable, they exceeded 0.8 times the simultaneous concentrations in serum for all specimens. Mean ratios of drug concentrations in bone and synovial fluid to that in serum at 0.5 h were 0.66 and 0.13, respectively. No definite adverse reactions to aztreonam were noted during this study. Patients 7 and 12 had postdose serum glutamic pyruvic transaminase elevations of 2.4 and 6.4 times normal, respectively. Patient 12 also'had elevated postdose serum glutamic oxalacetic transaminase (2.6 times normal) and lactate dehydrogenase (1.3 times normal) levels. Patients 8 and 9 had minor (less than twice normal) postdose elevations of serum glutamic oxalacetic transaminase and glutamic pyruvic transaminase, and patient 9 had a minor elevation of lactate dehydrogenase (1.2 times normal). These abnormalities were not associated with symptoms, required no treatment, and were considered to be possibly related to aztreonam.
Antibiotic efficacy in joint and bone infections requires an adequate spectrum of activity against the causative organism(s) in the environment of the infection (often anaerobic and acidotic) and penetration in adequate concentrations to the site of infection. The spectrum of activity of aztreonam against aerobic gram-negative bacilli is well documented. Aztreonam maintains good activity in an anaerobic environment, in contrast to the aminoglycosides (4).
Penetration of a wide variety of antimicrobial agents into joints has been reported. In general, single-dose (versus multiple-dose) studies (8, 21) and studies that corrected for blood contamination (1, 21, 24) detected lower penetration values. In dogs, cefazolin, penicillin, and cefamandole in serum rapidly equilibrate with the interstitial fluid of bone (5, 11, 16) . Specimens assayed after crushing give lower assay results than specimens assayed by elution (15) . Some authors have reported that inflammation has little effect on the penetration of antibiotics into joint or bone (27) .
The ratio of the aztreonam concentration in synovial fluid to that in serum compares favorably with that of streptomycin (50 to 75%) (30) , trimethoprim-sulfamethoxazole (100%) (31) , cefadroxil (43%) (23) , cephalothin (20 to 53%) (9, 26) , cefamandole (28.1%) (26) , gentamicin (88%) (6) , and tobramycin (95%) (6) . Aztreonam concentrations in cancellous bone (mean, 20% of that in concomitant serum) are similar to those of moxalactam (18%) (21) , cefazolin (18%) (21) , cefadroxil (23%) (23) , cephalothin (5 to 33%) (7, 9, 26) , cefamandole (5 to 20%) (18, 24, 26) , cefuroxime (10 to 70%) (7) , clindamycin (10 to 50%) (1, 28) , ceftazidime (54%) (1) , and amoxicillin (16.4%) (2) . However, the ranges for all these antibiotics were very wide (25, 28) , with some specimens showing no detectable concentrations. This may have been due to the variability of the specimens taken from patients with significant bone disease. There are few data available on the bone penetration of aminoglycosides, but clinical studies have shown a high failure rate when they are used as the sole treatment of gram-negative osteomyelitis (29) .
Because of the high treatment failure and morbidity rates seen in gram-negative bacillary arthritis and osteomyelitis (3, 10, 29) , newer, more active agents are required. Aztreonam has excellent activity against gram-negative microorganisms, beta-lactamase stability, activity in anaerobic and acidotic milieus, and good penetration into both synovial fluid and bone. These qualities are consistent with early reports of its efficacy in the treatment of gram-negative bone and joint infections (12, 22) . 
